GM Sees Impressive China Sales

General Motors (GM) has witnessed a staggering 67% rise in sales to 1.8 million vehicles in 2009, driven by Government incentives including tax cuts and subsidies.

GM has revealed that its joint venture with Shanghai Automotive Industries Corp. (SAIC) has shown a sales rise of 63.3% to 727,620 units. Further, the automaker’s joint venture with SAIC and Wuling became China's first automaker to exceed 1 million units in annual sales in 2009. Sales in SAIC-GM-Wuling joint venture rose 63.9% to 1.06 million vehicles.

The Chinese auto industry has been the apple of Beijing’s eye, basking in incentives for car owners to shift to more environment-friendly and fuel-efficient cars. Although the domestic automakers (especially small car manufacturers) received most of the incentives, foreign automakers benefited from them as well.

The collapse in the U.S. auto industry in 2009 was somewhat offset by the surging sales in China, making a stark shift in global vehicle volumes that was much quicker than anyone had expected. All these have led several global automakers, including GM, to strengthen their foothold in China's fast-growing market in order to drive sales amid slack demand elsewhere.

In 2009, GM's corporate operations in China saw a rapid expansion. The company launched a ground-breaking science laboratory and a vehicle safety research center in the country. GM also plans to expand in other parts of Asia with the help of Chinese automakers. Its joint venture with SAIC has announced to launch a new venture in India to produce and sell cars.

Add a Comment

Please login or register to post a comment

Email	Print	Share	Rate Pos	Rate Neg		Comment

Loading Stories...

ANALYST BLOG ARCHIVE

Dr Pepper Ups Shareholder Returns - Dr Pepper Snapple Group Inc. has increased its quarterly dividend by 6.3% to 34 cents per share, bringing its annualized dividend rate to $1.36 per share.

on February 9, 2012

Positive Results on Forest/Gedeon Drug - Preliminary top-line results were presented from a phase III study of cariprazine that was conducted in patients with acute mania associated with bipolar I disorder.

on February 9, 2012

Bristol-Myers, SNY Win Plavix Damages - Apotex settled the dispute regarding Plavix with co- developers Bristol-Myers and Sanofi

on February 9, 2012

Update on VPHM's Industrial Facility - ViroPharma Inc. recently announced that the US Food and Drug Administration has issued a complete response letter for Cinryze's industrial scale manufacturing facility.

on February 9, 2012

Outperform on Abiomed - We retain our Outperform recommendation on Abiomed following its impressive third quarter results.

on February 9, 2012

Newfield Kept at Neutral Rec - We are maintaining our Neutral recommendation on Texas-based Newfield Exploration Company.

on February 9, 2012

Citi Entangled in Lawsuit Again - Citibank, the banking unit of Citi, has been sued by Lehman for wrongly confiscating nearly $2.5 billion, which was transferred by Lehman just before its bankruptcy filing in 2008.

on February 9, 2012

Aflac Values $750M Notes - Aflac Inc. announced the pricing of long-term fixed rate notes worth $750 million in two tranches

on February 9, 2012

O'Charley's to Join Fidelity - O'Charley's agreed to be acquired by Fidelity National Financial.

on February 9, 2012

Contracts Flowing in for Northrop - Northrop Grumman Corporation has received a contract worth $103 million from the U.S. Department of Defense and worth $19 million from U.S. Naval Supply Systems Command.

on February 9, 2012

<< Previous 10 Stories

View All

Next 10 Stories>>